Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
SEC Accession No. 0001193125-19-051924
Filing Date
2019-02-26
Accepted
2019-02-26 16:05:16
Documents
7
Effectiveness Date
2019-02-26

Document Format Files

Seq Description Document Type Size
1 POSASR d712727dposasr.htm POSASR 448792
2 EX-5.1 d712727dex51.htm EX-5.1 38911
3 EX-23.1 d712727dex231.htm EX-23.1 1370
4 GRAPHIC g712727g01k83.jpg GRAPHIC 36381
5 GRAPHIC g712727g63k04.jpg GRAPHIC 37567
6 GRAPHIC g712727n2.jpg GRAPHIC 9729
7 GRAPHIC g712727pic1.jpg GRAPHIC 3561
  Complete submission text file 0001193125-19-051924.txt   610589
Mailing Address 6400 WESTWIND WAY SUITE A CRESTWOOD KY 40014
Business Address 6400 WESTWIND WAY SUITE A CRESTWOOD KY 40014 502-241-4114
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

EIN.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: POSASR | Act: 33 | File No.: 333-229091 | Film No.: 19633368
SIC: 2834 Pharmaceutical Preparations